Tamra Sami

Perth

Staff Writer at BioWorld

Staff Writer at Clarivate

Science writer, editor, publication manager with product development, Asia and emerging markets expertise.

Featured in: Favicon

bioworld.com Favicon

usnews.com Favicon

endpts.com Favicon

biopharmadive.com Favicon

centerwatch.com Favicon

biocentury.com Favicon

pharmamedtechbi.com

Articles

Keymed launching Stapokibart, advancing pipeline, with $125M raise

1 week ago | bioworld.com | Tamra Sami

Home » Keymed launching Stapokibart, advancing pipeline, with $125M raiseKeymed launching Stapokibart, advancing pipeline, with $125M raiseKeymed Biosciences Co. Ltd. has raised HK$982 million (US$125 million) in a placement on the Hong Kong Stock Exchange (HKEX:2162) to commercialize its IL-4Rα monoclonal antibody CM-310 branded as Stapokibart, and to advance its larger pipeline. BioWorld Financings Monoclonal antibody Mezzanine Asia-Pacific China
Immuno Cure, Pharmjet partner on needle-free HIV vaccine trial

1 week ago | bioworld.com | Tamra Sami

Immuno Cure, Pharmjet partner on needle-free HIV vaccine trialImmuno Cure Biotech Ltd. is collaborating with Pharmajet Inc. to evaluate the safety and immunogenicity of its HIV therapeutic DNA vaccine, Icvax, delivered via Pharmajet's innovative Tropis needle-free injection system. BioWorld Clinical Infection Vaccine
Avata, Oceanus partner on cannabidiol for epilepsy, schizophrenia

1 week ago | bioworld.com | Tamra Sami

How the U.S. FDA might respond became a serious question for Wall Street as Sarepta Therapeutics Inc. made known a second death due to acute liver failure with...
New orphan drug, CSL’s garadacimab, cleared for hereditary angioedema

1 week ago | bioworld.com | Karen Carey |Tamra Sami

New orphan drug, CSL’s garadacimab, cleared for hereditary angioedemaFollowing a complete response letter issued last October over CMC issues, CSL Behring LLC gained U.S. FDA approval June 16 of its humanized anti-factor XIIa monoclonal antibody, garadacimab (CSL-312), to prevent hereditary angioedema attacks. BioWorld Regulatory Dermatologic Monoclonal antibody Asia-Pacific Australia U.S. FDA
Reset Moves to promote well-being in children with neurodivergence

1 week ago | bioworld.com | Tamra Sami

Reset Moves to promote well-being in children with neurodivergenceFocused on promoting well-being amongst children with neurodivergence, Reset Moves Pty Ltd. created app-based games to help children not only focus with greater clarity, but also to better help them re-engage in certain settings. BioWorld MedTech Neurology/psychiatric Digital health SAAS Asia-Pacific
Microneedles could solve vaccine distribution challenges

2 weeks ago | bioworld.com | Tamra Sami

Corestemchemon Inc. is planning to file a BLA for Neuronata-R (lenzumestrocel) by the end of 2025 to gain accelerated approval from the U.S. FDA, company...
Ascletis’ denifanstat meets phase III endpoints in acne

2 weeks ago | bioworld.com | Tamra Sami

Ascletis Pharma Inc.’s once-daily oral fatty acid synthase (FASN) inhibitor, denifanstat, demonstrated statistically significant and clinically meaningful improvements compared to placebo, meeting all primary and secondary endpoints in a phase III trial for moderate to severe acne vulgaris. Conducted in China, the randomized, double-blind, placebo-controlled, multicenter trial evaluated the safety and efficacy of denifanstat (ASC-40) in 480 patients with moderate to severe acne vulgaris.
ASCO 2025: Dizal's new chemical entities for lung, blood cancers

2 weeks ago | bioworld.com | Tamra Sami

Dizal (Jiangsu) Pharmaceutical Co. Ltd.’s LYN/BTK dual inhibitor, DZD-8586, saw tumor shrinkage in 94.1% of patients with relapsed or refractory (r/r) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) following Bruton's tyrosine kinase (BTK) inhibitors, the company reported during an oral presentation at the American Society of Clinical Oncology (ASCO) 2025 conference.
Dizal's new chemical entities for lung, blood cancers

2 weeks ago | bioworld.com | Tamra Sami

ASCO 2025Dizal's new chemical entities for lung, blood cancersDizal (Jiangsu) Pharmaceutical Co. Ltd.’s LYN/BTK dual inhibitor, DZD-8586, saw tumor shrinkage in 94.1% of patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma following Bruton's tyrosine kinase inhibitors, the company reported during an oral presentation at the American Society of Clinical Oncology (ASCO) 2025 conference.
Microneedles could solve vaccine distribution challenges

3 weeks ago | bioworld.com | Tamra Sami

Ligachem Biosciences Inc. signed two license agreements with Novarock Biotherapeutics Inc., a subsidiary of CSPC Pharmaceutical Group Ltd., to bring in two of...